Last reviewed · How we verify
Carboplatin, Pemetrexed and Bevacizumab
Carboplatin, Pemetrexed and Bevacizumab is a Platinum-based chemotherapy, Antifolate, Monoclonal antibody Small molecule drug developed by Christiana Care Health Services. It is currently in Phase 2 development for Non-small cell lung cancer, Ovarian cancer, Advanced gastric cancer. Also known as: Paraplatin, Alimta, Avastin.
Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell replication. Pemetrexed is an antifolate drug that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to DNA synthesis inhibition. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing angiogenesis.
Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell replication. Pemetrexed is an antifolate drug that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to DNA synthesis inhibition. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing angiogenesis. Used for Non-small cell lung cancer, Ovarian cancer, Advanced gastric cancer.
At a glance
| Generic name | Carboplatin, Pemetrexed and Bevacizumab |
|---|---|
| Also known as | Paraplatin, Alimta, Avastin |
| Sponsor | Christiana Care Health Services |
| Drug class | Platinum-based chemotherapy, Antifolate, Monoclonal antibody |
| Target | DNA, Thymidylate synthase, VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Carboplatin's mechanism of action involves the formation of platinum-DNA adducts, which interfere with DNA replication and transcription. Pemetrexed's inhibition of thymidylate synthase and other enzymes leads to a decrease in DNA synthesis and cell proliferation. Bevacizumab's binding to VEGF-A prevents the interaction with its receptor, thereby inhibiting the signaling pathways that promote angiogenesis.
Approved indications
- Non-small cell lung cancer, Ovarian cancer, Advanced gastric cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease (PHASE2)
- Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin, Pemetrexed and Bevacizumab CI brief — competitive landscape report
- Carboplatin, Pemetrexed and Bevacizumab updates RSS · CI watch RSS
- Christiana Care Health Services portfolio CI
Frequently asked questions about Carboplatin, Pemetrexed and Bevacizumab
What is Carboplatin, Pemetrexed and Bevacizumab?
How does Carboplatin, Pemetrexed and Bevacizumab work?
What is Carboplatin, Pemetrexed and Bevacizumab used for?
Who makes Carboplatin, Pemetrexed and Bevacizumab?
Is Carboplatin, Pemetrexed and Bevacizumab also known as anything else?
What drug class is Carboplatin, Pemetrexed and Bevacizumab in?
What development phase is Carboplatin, Pemetrexed and Bevacizumab in?
What are the side effects of Carboplatin, Pemetrexed and Bevacizumab?
What does Carboplatin, Pemetrexed and Bevacizumab target?
Related
- Drug class: All Platinum-based chemotherapy, Antifolate, Monoclonal antibody drugs
- Target: All drugs targeting DNA, Thymidylate synthase, VEGF-A
- Manufacturer: Christiana Care Health Services — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer, Ovarian cancer, Advanced gastric cancer
- Also known as: Paraplatin, Alimta, Avastin
- Compare: Carboplatin, Pemetrexed and Bevacizumab vs similar drugs
- Pricing: Carboplatin, Pemetrexed and Bevacizumab cost, discount & access